Sales of Leqembi® totaled 20.7 billion yen in the fourth quarter 2025
BioAge Labs, Inc. (BIOA)
Last bioage labs, inc. earnings: 8/3 07:00 am
Check Earnings Report
US:NYSE Investor Relations:
investor.bio-amber.com
Company Research
Source: PR Newswire
STOCKHOLM, Feb. 6, 2026 /PRNewswire/ -- BioArctic AB's (publ) (Nasdaq Stockholm: BIOA B) partner Eisai today published the preliminary global revenue for Leqembi for the fourth quarter 2025, in conjunction with their partner Biogen's fourth quarter report. In total, sales of JPY 20.7 billion were recorded in the period. This results in a royalty to BioArctic amounting to SEK 127 million, which is an increase of approximately 31 percent compared to the royalty obtained by BioArctic for the fourth quarter 2024. The strong appreciation of the Swedish krona during 2025 has had a significant impact on the growth of royalty received in the fourth quarter. With constant exchange rates, the increase in recorded royalty in SEK would have been approximately 50 percent.Eisai's results for their third quarter FY2025 (Oct-Dec 2025) will be published on February 9, 2026.BioArctic's report for the full year 2025 will be published on February 18, 2026, at 08:00 CET.This information is information tha
Show less
Read more
Impact Snapshot
Event Time:
BIOA
Last Price
Price Change
Price Change%
Volume Shares
Max Up
Max Down
%
Volume Ratio
Performance Comparison
Updated
|
Event Day
Stock performance from the time of news release until the following 4pm ET market close
|
Last price at news event
|
Since Event
Multi-day stock performance from the time of the news release
|
|---|---|---|
|
EVENT DAY
Stock performance from the time of news release until the following 4pm ET market close
|
LAST
PRICE AT NEWS EVENT |
SINCE EVENT
Multi-day stock performance from the time of the news release
|
| Last Price | ||
| VWAP | ||
|
High:
|
Max Up |
High:
|
|
Low:
|
Max Down |
Low:
|
|
%
|
Post news range |
%
|
|
|
Price change |
|
|
|
Price Change Percentage |
|
|
|
S&P 500 (SPX) |
|
|
%
|
Volume ratio |
%
|
| Volume | ||
| Ticks | ||
|
|
Avg transaction size |
|
Don't Miss Out On The Next BIG Stock Move
Event day
Event Day Chart will not be displayed beyond 90-day period of the event
Performance since event
Time And Velocity Analysis
Be the first to know
Opt in for alerts from News Quantifed
Sign Up Today
Opt-in for
BIOA alerts
Learn More With NQ
Reading the Impact Report
Help Me Understand This Data
Help Me Understand This Data
How NQ Works
What is news-based trading?
And why is it so successful?
And why is it so successful?
Movers & Shakers
The biggest gainers and losers and WHY it moved
BIOA alerts
High impacting BioAge Labs, Inc. news events
Weekly update
A roundup of the hottest topics
BIOA
News
- Sales of Leqembi® totaled 20.7 billion yen in the fourth quarter 2025PR Newswire
- BioAge Labs (NASDAQ:BIOA) was given a new $23.00 price target on by analysts at Morgan Stanley.MarketBeat
- BioAge Labs (NASDAQ:BIOA) was upgraded by analysts at <a style="font-weight:bold" href="https://www.wallstreetzen.com/newsletters/zen-ratings?ticker=BIOA&utm_campaign=getratings&utm_medium=online&utm_source=MarketBeat">Wall Street Zen</aMarketBeat
- BioAge Labs (NASDAQ:BIOA) had its "sell (d-)" rating reaffirmed by analysts at <a style="font-weight:bold" href="https://weissratings.com/">Weiss Ratings</a>.MarketBeat
- BioAge Labs (NASDAQ:BIOA) is now covered by analysts at Piper Sandler. They set an "overweight" rating on the stock.MarketBeat
BIOA
Earnings
- 11/6/25 - Beat
BIOA
Sec Filings
- 2/3/26 - Form 4
- 2/3/26 - Form 4
- 2/2/26 - Form 144
- BIOA's page on the SEC website